Bristol-Myers Squibb Company (BMY) reported an amendment to a previously filed SEC Form 3, indicating a correction in the beneficial ownership of securities by reporting person Michael R. McMullen. The amendment, dated July 2, 2024, corrects the amount of common stock beneficially owned as of July 1, 2024, which is now reported to be 1,000 shares held indirectly through a family trust. Additionally, McMullen is associated with a call option obligation to sell 500 shares of common stock at a price of $46, exercisable between June 24, 2024, and expiring on August 16, 2024. McMullen serves as a director and is also a trustee and beneficiary of the family trust holding the securities. The filing was signed by attorney-in-fact Lisa A. Atkins on behalf of McMullen on July 31, 2024.

Bristol-Myers Squibb Company (BMY) reported an amendment to a previously filed SEC Form 3, indicating a correction in the beneficial ownership of securities by reporting person Michael R. McMullen. The amendment, dated July 2, 2024, corrects the amount of common stock beneficially owned as of July 1, 2024, which is now reported to be 1,000 shares held indirectly through a family trust. Additionally, McMullen is associated with a call option obligation to sell 500 shares of common stock at a price of $46, exercisable between June 24, 2024, and expiring on August 16, 2024. McMullen serves as a director and is also a trustee and beneficiary of the family trust holding the securities. The filing was signed by attorney-in-fact Lisa A. Atkins on behalf of McMullen on July 31, 2024.